DongKook Pharmaceutical Co. Ltd (086450) — Capital Reinvestment Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Capital Reinvestment Ratio of 0.60x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩22.58 Billion) in capital expenditures (₩13.54 Billion). See free cash flow generation of DongKook Pharmaceutical Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
DongKook Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks DongKook Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for DongKook Pharmaceutical Co. Ltd from 2013 to 2025. For live market cap and broader valuation context, see DongKook Pharmaceutical Co. Ltd (086450) total market value.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | ₩68.76 Billion | ₩46.00 Billion | ▲ +65.2% |
| 2024 | 0.40x | ₩76.09 Billion | ₩30.80 Billion | ▼ -57.0% |
| 2023 | 0.94x | ₩41.79 Billion | ₩39.35 Billion | ▼ -24.8% |
| 2022 | 1.25x | ₩40.91 Billion | ₩51.23 Billion | ▲ +9.6% |
| 2021 | 1.14x | ₩44.65 Billion | ₩51.01 Billion | ▲ +70.5% |
| 2020 | 0.67x | ₩59.11 Billion | ₩39.61 Billion | ▲ +85.3% |
| 2019 | 0.36x | ₩69.48 Billion | ₩25.13 Billion | ▼ -84.1% |
| 2018 | 2.27x | ₩33.21 Billion | ₩75.46 Billion | ▲ +457.8% |
| 2017 | 0.41x | ₩28.66 Billion | ₩11.67 Billion | ▲ +66.9% |
| 2016 | 0.24x | ₩39.41 Billion | ₩9.62 Billion | ▼ -30.9% |
| 2015 | 0.35x | ₩27.14 Billion | ₩9.60 Billion | ▼ -40.8% |
| 2014 | 0.60x | ₩22.74 Billion | ₩13.59 Billion | ▲ +197.2% |
| 2013 | 0.20x | ₩19.86 Billion | ₩3.99 Billion | — |